Deep Track Capital LP Invests $38.92 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Deep Track Capital LP purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,540,132 shares of the biopharmaceutical company's stock, valued at approximately $38,919,000. Celldex Therapeutics accounts for 1.4% of Deep Track Capital LP's holdings, making the stock its 23rd biggest position. Deep Track Capital LP owned approximately 2.32% of Celldex Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 878 shares during the period. Headlands Technologies LLC acquired a new position in Celldex Therapeutics during the 4th quarter valued at about $81,000. KBC Group NV increased its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics in the 4th quarter worth $121,000.

Celldex Therapeutics Stock Down 6.1 %

NASDAQ CLDX traded down $1.19 during trading on Friday, hitting $18.33. The stock had a trading volume of 1,001,538 shares, compared to its average volume of 888,307. The firm has a 50 day moving average price of $18.99 and a 200 day moving average price of $22.88. The company has a market capitalization of $1.22 billion, a PE ratio of -7.13 and a beta of 1.39. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million. On average, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on CLDX. Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday. UBS Group cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday. The Goldman Sachs Group decreased their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.